196 related articles for article (PubMed ID: 27512667)
1. The emerging therapeutic potential of the oncolytic immunotherapeutic Pexa-Vec (JX-594).
Breitbach CJ; Bell JC; Hwang TH; Kirn DH; Burke J
Oncolytic Virother; 2015; 4():25-31. PubMed ID: 27512667
[TBL] [Abstract][Full Text] [Related]
2. Oncolytic and immunotherapeutic vaccinia induces antibody-mediated complement-dependent cancer cell lysis in humans.
Kim MK; Breitbach CJ; Moon A; Heo J; Lee YK; Cho M; Lee JW; Kim SG; Kang DH; Bell JC; Park BH; Kirn DH; Hwang TH
Sci Transl Med; 2013 May; 5(185):185ra63. PubMed ID: 23677592
[TBL] [Abstract][Full Text] [Related]
3. Vaccinia-based oncolytic immunotherapy Pexastimogene Devacirepvec in patients with advanced hepatocellular carcinoma after sorafenib failure: a randomized multicenter Phase IIb trial (TRAVERSE).
Moehler M; Heo J; Lee HC; Tak WY; Chao Y; Paik SW; Yim HJ; Byun KS; Baron A; Ungerechts G; Jonker D; Ruo L; Cho M; Kaubisch A; Wege H; Merle P; Ebert O; Habersetzer F; Blanc JF; Rosmorduc O; Lencioni R; Patt R; Leen AM; Foerster F; Homerin M; Stojkowitz N; Lusky M; Limacher JM; Hennequi M; Gaspar N; McFadden B; De Silva N; Shen D; Pelusio A; Kirn DH; Breitbach CJ; Burke JM
Oncoimmunology; 2019; 8(8):1615817. PubMed ID: 31413923
[TBL] [Abstract][Full Text] [Related]
4. Phase 1b Trial of Biweekly Intravenous Pexa-Vec (JX-594), an Oncolytic and Immunotherapeutic Vaccinia Virus in Colorectal Cancer.
Park SH; Breitbach CJ; Lee J; Park JO; Lim HY; Kang WK; Moon A; Mun JH; Sommermann EM; Maruri Avidal L; Patt R; Pelusio A; Burke J; Hwang TH; Kirn D; Park YS
Mol Ther; 2015 Sep; 23(9):1532-40. PubMed ID: 26073886
[TBL] [Abstract][Full Text] [Related]
5. Phase 1 study of intratumoral Pexa-Vec (JX-594), an oncolytic and immunotherapeutic vaccinia virus, in pediatric cancer patients.
Cripe TP; Ngo MC; Geller JI; Louis CU; Currier MA; Racadio JM; Towbin AJ; Rooney CM; Pelusio A; Moon A; Hwang TH; Burke JM; Bell JC; Kirn DH; Breitbach CJ
Mol Ther; 2015 Mar; 23(3):602-8. PubMed ID: 25531693
[TBL] [Abstract][Full Text] [Related]
6. PHOCUS: A Phase 3, Randomized, Open-Label Study of Sequential Treatment with Pexa-Vec (JX-594) and Sorafenib in Patients with Advanced Hepatocellular Carcinoma.
Abou-Alfa GK; Galle PR; Chao Y; Erinjeri J; Heo J; Borad MJ; Luca A; Burke J; Pelusio A; Agathon D; Lusky M; Breitbach C; Qin S; Gane E
Liver Cancer; 2024 Jun; 13(3):248-264. PubMed ID: 38756145
[TBL] [Abstract][Full Text] [Related]
7. Neoadjuvant Intravenous Oncolytic Vaccinia Virus Therapy Promotes Anticancer Immunity in Patients.
Samson A; West EJ; Carmichael J; Scott KJ; Turnbull S; Kuszlewicz B; Dave RV; Peckham-Cooper A; Tidswell E; Kingston J; Johnpulle M; da Silva B; Jennings VA; Bendjama K; Stojkowitz N; Lusky M; Prasad KR; Toogood GJ; Auer R; Bell J; Twelves CJ; Harrington KJ; Vile RG; Pandha H; Errington-Mais F; Ralph C; Newton DJ; Anthoney A; Melcher AA; Collinson F
Cancer Immunol Res; 2022 Jun; 10(6):745-756. PubMed ID: 35439304
[TBL] [Abstract][Full Text] [Related]
8. Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer.
Heo J; Reid T; Ruo L; Breitbach CJ; Rose S; Bloomston M; Cho M; Lim HY; Chung HC; Kim CW; Burke J; Lencioni R; Hickman T; Moon A; Lee YS; Kim MK; Daneshmand M; Dubois K; Longpre L; Ngo M; Rooney C; Bell JC; Rhee BG; Patt R; Hwang TH; Kirn DH
Nat Med; 2013 Mar; 19(3):329-36. PubMed ID: 23396206
[TBL] [Abstract][Full Text] [Related]
9. Gene expression profiling of hematologic malignant cell lines resistant to oncolytic virus treatment.
Lee NH; Kim M; Oh SY; Kim SG; Kwon HC; Hwang TH
Oncotarget; 2017 Jan; 8(1):1213-1225. PubMed ID: 27901484
[TBL] [Abstract][Full Text] [Related]
10. Pexa-Vec double agent engineered vaccinia: oncolytic and active immunotherapeutic.
Breitbach CJ; Parato K; Burke J; Hwang TH; Bell JC; Kirn DH
Curr Opin Virol; 2015 Aug; 13():49-54. PubMed ID: 25900822
[TBL] [Abstract][Full Text] [Related]
11. A Phase 2, Open-Label, Randomized Study of Pexa-Vec (JX-594) Administered by Intratumoral Injection in Patients with Unresectable Primary Hepatocellular Carcinoma.
Breitbach CJ; Moon A; Burke J; Hwang TH; Kirn DH
Methods Mol Biol; 2015; 1317():343-57. PubMed ID: 26072416
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of oncolytic viruses in advanced or metastatic cancer: a network meta-analysis.
Xie R; Bi X; Shang B; Zhou A; Shi H; Shou J
Virol J; 2021 Jul; 18(1):158. PubMed ID: 34332591
[TBL] [Abstract][Full Text] [Related]
13. Targeted and armed oncolytic poxviruses for cancer: the lead example of JX-594.
Breitbach CJ; Thorne SH; Bell JC; Kirn DH
Curr Pharm Biotechnol; 2012 Jul; 13(9):1768-72. PubMed ID: 21740365
[TBL] [Abstract][Full Text] [Related]
14. Generation of novel oncolytic vaccinia virus with improved intravenous efficacy through protection against complement-mediated lysis and evasion of neutralization by vaccinia virus-specific antibodies.
Lee N; Jeon YH; Yoo J; Shin SK; Lee S; Park MJ; Jung BJ; Hong YK; Lee DS; Oh K
J Immunother Cancer; 2023 Jan; 11(1):. PubMed ID: 36717184
[TBL] [Abstract][Full Text] [Related]
15. Systemic Injection of Oncolytic Vaccinia Virus Suppresses Primary Tumor Growth and Lung Metastasis in Metastatic Renal Cell Carcinoma by Remodeling Tumor Microenvironment.
Park JS; Lee ME; Jang WS; Kim J; Park SM; Oh K; Lee N; Ham WS
Biomedicines; 2022 Jan; 10(1):. PubMed ID: 35052851
[TBL] [Abstract][Full Text] [Related]
16. Oncolytic Virotherapy and Gene Therapy Strategies for Hepatobiliary Cancers.
Yamada T; Hamano Y; Hasegawa N; Seo E; Fukuda K; Yokoyama KK; Hyodo I; Abei M
Curr Cancer Drug Targets; 2018; 18(2):188-201. PubMed ID: 28359239
[TBL] [Abstract][Full Text] [Related]
17. Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial.
Park BH; Hwang T; Liu TC; Sze DY; Kim JS; Kwon HC; Oh SY; Han SY; Yoon JH; Hong SH; Moon A; Speth K; Park C; Ahn YJ; Daneshmand M; Rhee BG; Pinedo HM; Bell JC; Kirn DH
Lancet Oncol; 2008 Jun; 9(6):533-42. PubMed ID: 18495536
[TBL] [Abstract][Full Text] [Related]
18. Critical analysis of an oncolytic herpesvirus encoding granulocyte-macrophage colony stimulating factor for the treatment of malignant melanoma.
Hughes T; Coffin RS; Lilley CE; Ponce R; Kaufman HL
Oncolytic Virother; 2014; 3():11-20. PubMed ID: 27512660
[TBL] [Abstract][Full Text] [Related]
19. Oncolytic and immunologic cancer therapy with GM-CSF-armed vaccinia virus of Tian Tan strain Guang9.
Deng L; Fan J; Guo M; Huang B
Cancer Lett; 2016 Mar; 372(2):251-7. PubMed ID: 26803055
[TBL] [Abstract][Full Text] [Related]
20. Oncolytic virus therapy in Japan: progress in clinical trials and future perspectives.
Taguchi S; Fukuhara H; Todo T
Jpn J Clin Oncol; 2019 Mar; 49(3):201-209. PubMed ID: 30462296
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
